Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eun Oh

Internal Medicine Oro Valley, AZ Medical Doctor

NPI 1558391672 CMS profile 24667

555 E Vuelta Caminata Del Rio, Oro Valley, AZ 85737

Open in the dashboard

General payments

$3,026

181 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eun Oh of Oro Valley, AZ is reported in the CMS Open Payments database as having received $3,026 across 181 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $646 27
2024 General $747 36
2023 General $267 16
2022 General $425 26
2021 General $174 12
2020 General $154 10
2019 General $613 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eun Oh
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Eun Oh were reported at $646. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Eun Oh Internal Medicine median Middle half National median
2019 $613 $159 $48–$570 $163
2020 $154 $119 $33–$402 $114
2021 $174 $135 $37–$521 $132
2022 $425 $141 $42–$496 $149
2023 $267 $149 $45–$519 $160
2024 $747 $154 $47–$537 $164
2025 $646 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $793 59 payments
  2. AstraZeneca Pharmaceuticals LP $656 19 payments
  3. Radius Health, Inc. $241 13 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $194 13 payments
  5. Novo Nordisk Inc $175 20 payments
  6. Novartis Pharmaceuticals Corporation $163 9 payments
  7. Lilly USA, LLC $145 9 payments
  8. Pfizer Inc. $125 7 payments
  9. AbbVie, Inc. $114 6 payments
  10. Janssen Pharmaceuticals, Inc $83 5 payments
  11. Other $338 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,025 180 payments
  2. Education $1 1 payment
Products named General payments · program years 2019–2025
  1. Repatha $451 35 payments
  2. FARXIGA $364 14 payments
  3. EVENITY $331 23 payments
  4. Prolia $330 23 payments
  5. TEZSPIRE $250 2 payments
  6. Otezla $218 18 payments
  7. XIFAXAN $209 14 payments
  8. AIRSUPRA $180 2 payments
  9. LEQVIO $163 9 payments
  10. Ozempic $156 18 payments
  11. Other $1,562 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 85 drugs

Part D claims

3,551

Median for Internal Medicine: 777

Drug cost

$647,583

Median for Internal Medicine: $73,373

Branded share of claims

27.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 127 $188,907
Rybelsus Semaglutide Brand 66 $108,818
Repatha Sureclick Evolocumab Brand 68 $57,509
Xarelto Rivaroxaban Brand 34 $51,964
Creon Lipase/Protease/Amylase Brand 22 $37,193
Eliquis Apixaban Brand 31 $32,949
Farxiga Dapagliflozin Propanediol Brand 31 $28,562
Januvia Sitagliptin Phosphate Brand 17 $17,356
Trintellix Vortioxetine Hydrobromide Brand 12 $13,784
Synthroid Levothyroxine Sodium Brand 100 $10,576

The 10 drugs with the highest cost, of 85 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$56,536

Of which drugs: $5,920

Medicare patients

171

Average age 79

Services billed

1,010

129 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 49%
Osteoporosis 49%
Chronic kidney disease 43%
Diabetes 25%
Ischemic heart disease 19%
Atrial fibrillation 18%
Heart failure 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 48 48 $3,874
Vaccine for influenza for injection into muscle 90662 Office 25 25 $2,046

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $125
$125 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $91
$91 31 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $75
$75 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $62
$62 — —
Tymlos
  • Radius Health, Inc. $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

181 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record